These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 18628067)

  • 1. Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer.
    Martínez-Iglesias O; Ruiz-Llorente L; Sánchez-Martínez R; García L; Zambrano A; Aranda A
    Clin Transl Oncol; 2008 Jul; 10(7):395-8. PubMed ID: 18628067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone deacetylase inhibitors: Potential in cancer therapy.
    Marks PA; Xu WS
    J Cell Biochem; 2009 Jul; 107(4):600-8. PubMed ID: 19459166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone deacetylase inhibitors: molecular mechanisms of action.
    Xu WS; Parmigiani RB; Marks PA
    Oncogene; 2007 Aug; 26(37):5541-52. PubMed ID: 17694093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylase inhibitors: overview and perspectives.
    Dokmanovic M; Clarke C; Marks PA
    Mol Cancer Res; 2007 Oct; 5(10):981-9. PubMed ID: 17951399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors.
    Slingerland M; Guchelaar HJ; Gelderblom H
    Anticancer Drugs; 2014 Feb; 25(2):140-9. PubMed ID: 24185382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy.
    Jazirehi AR
    Anticancer Drugs; 2010 Oct; 21(9):805-13. PubMed ID: 20679890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors.
    Frew AJ; Johnstone RW; Bolden JE
    Cancer Lett; 2009 Aug; 280(2):125-33. PubMed ID: 19359091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy.
    Singh AK; Bishayee A; Pandey AK
    Nutrients; 2018 Jun; 10(6):. PubMed ID: 29882797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone deacetylase inhibitors selectively suppress expression of HDAC7.
    Dokmanovic M; Perez G; Xu W; Ngo L; Clarke C; Parmigiani RB; Marks PA
    Mol Cancer Ther; 2007 Sep; 6(9):2525-34. PubMed ID: 17876049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug.
    Marks PA; Breslow R
    Nat Biotechnol; 2007 Jan; 25(1):84-90. PubMed ID: 17211407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological characterization of histone deacetylase inhibitor and tumor cell-growth inhibition properties of new benzofuranone compounds.
    Blanquart C; François M; Charrier C; Bertrand P; Gregoire M
    Curr Cancer Drug Targets; 2011 Oct; 11(8):919-28. PubMed ID: 21762083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted histone deacetylase inhibition for cancer therapy.
    Vigushin DM; Coombes RC
    Curr Cancer Drug Targets; 2004 Mar; 4(2):205-18. PubMed ID: 15032670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase inhibitors: design, structure-activity relationships and therapeutic implications for cancer.
    Marson CM
    Anticancer Agents Med Chem; 2009 Jul; 9(6):661-92. PubMed ID: 19601748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylase inhibitors: anticancer compounds.
    Smith KT; Workman JL
    Int J Biochem Cell Biol; 2009 Jan; 41(1):21-5. PubMed ID: 18845268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone deacetylase inhibitors in hematological malignancies and solid tumors.
    Chun P
    Arch Pharm Res; 2015 Jun; 38(6):933-49. PubMed ID: 25653088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylase inhibitors--turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases.
    Riester D; Hildmann C; Schwienhorst A
    Appl Microbiol Biotechnol; 2007 Jun; 75(3):499-514. PubMed ID: 17377788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zn(II)-dependent histone deacetylase inhibitors: suberoylanilide hydroxamic acid and trichostatin A.
    Codd R; Braich N; Liu J; Soe CZ; Pakchung AA
    Int J Biochem Cell Biol; 2009 Apr; 41(4):736-9. PubMed ID: 18725319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy.
    Carew JS; Giles FJ; Nawrocki ST
    Cancer Lett; 2008 Sep; 269(1):7-17. PubMed ID: 18462867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HDAC inhibitors for the treatment of cancer.
    Secrist JP; Zhou X; Richon VM
    Curr Opin Investig Drugs; 2003 Dec; 4(12):1422-7. PubMed ID: 14763127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic therapy of cancer with histone deacetylase inhibitors.
    Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
    J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.